ADVENTA BERHAD
(Company No : 200301016113 (618533-M))
(Incorporated in Malaysia)
THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2025

UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

1. BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2024. The explanatory notes attached to the interim financial statements explain events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2024.

The audited financial statements of the Group for the year ended 31 December 2024 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computation adopted in the preparation of the financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2024.

2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding audited financial statements for the year ended 31 December 2024 were not subject to any qualification.

3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE, OR INCIDENCE

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

4. CHANGES IN ESTIMATES

There were no changes in estimates that have had a material effect on the current quarter's results.

5. DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.

6. DIVIDENDS PAID

There was no dividend paid during the current quarter under review.

UNAUDITED NOTES TO FINANCIAL STATEMENTS

7. INVESTMENT

	As at 30-Sep-25 RM ('000)	As at 31-Dec-24 RM ('000)
Unquoted shares at cost	11,500	11,500

8. TRADE AND OTHER RECEIVABLES

	As at 30-Sep-25 RM ('000)	As at 31-Dec-24 RM ('000)
Trade Receivables		
Third parties	15,153	18,616
Allowance for impairment loss	(99)	(1,447)
	15,054	17,169
Other Receivables		
Third and Related parties	2,648	2,550
	2,648	2,550
Deposits and Prepayments	2,713	3,051
	20,415	22,770

a) Trade Receivables

The Group's normal trade credit term ranges from 30 to 90 days (2024: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts, which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ECLs) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9.

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

	As at 30-Sep-25 RM ('000)	As at 31-Dec-24 RM ('000)
Not past due	5,396	15,272
Past due:		
- Less than 30 days	2,531	31
- 31 to 60 days	542	304
- 61 to 90 days	303	338
- More than 90 days	6,381	2,671
	15,153	18,616
Less: Loss allowance		
- Collectively impaired	(99)	(99)
- Individually impaired	-	(1,348)
Trade Receivable net	15,054	17,169

Credit impaired.

Trade receivables are determined to be impaired at the reporting date are debts that are deemed to be difficult to collect in full or in part for respective reasons. These receivables are not secured by any collateral or credit enhancements.

9. SEGMENTAL INFORMATION

Healthcare: The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies.

The Group's segmental revenue and profit/(loss) before tax (PBT/(LBT)) for the current quarter are as follows:

Revenue	**Individual Quarter Ended**		**Cumulative Quarter Ended**	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
Segment	**RM ('000)**	**RM ('000)**	**RM ('000)**	**RM ('000)**
Healthcare	15,784	15,928	49,516	42,767
Corporate	270	210	810	630
Elimination	(4,296)	(719)	(11,067)	(2,127)
Total	**11,758**	**15,419**	**39,259**	**41,270**

UNAUDITED NOTES TO FINANCIAL STATEMENTS

(LBT)/PBT result	Individual Quarter Ended		Cumulative Quarter Ended	
	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24
Segment	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	917	1,345	3,071	2,879
Corporate	(739)	(683)	(2,154)	(1,571)
Elimination	-	-	-	-
Total	**178**	**662**	**917**	**1,308**

10. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.

11. SIGNIFICANT EVENTS

There are no material events subsequent to the end of the reporting period under review that have not been reflected in the quarterly financial statements.

12. CHANGES IN COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the financial period ended 30 September 2025 and subsequent to financial period.

13. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

14. CAPITAL COMMITMENTS

There were no commitments for the purchase of property, plant and equipment at the financial period ended 30 September 2025.

UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART B – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS

15. PERFORMANCE REVIEW

	Individual Quarter Ended 3Q 2025	Individual Quarter Ended 3Q 2024	Changes	Changes
	RM ('000)	RM ('000)	RM (‘000)	%
Revenue	11,758	15,419	(3,661)	(23.74%)
Profit before tax/ (Loss before tax)	178	662	(484)	(73.11%)

The Group’s revenue declined by 23.74% to RM11.7 million in 3Q FY2025 from RM15.4 million in the corresponding quarter of the previous year. Changes in product and customer mix during the quarter to align with market strategies in product and customer base.

Profit before tax decreased by 73.11% to RM178,000 in 3Q FY2025 compared to RM662,000 in 3Q FY2024. This drop is attributed to lower sales in the quarter with expenses edging higher from manufacturing operations.

16. COMPARISON WITH PRECEDING QUARTER’S RESULTS

	Reporting Quarter 3Q 2025	Previous Quarter 2Q 2025	Changes	Changes
	RM ('000)	RM ('000)	RM (‘000)	%
Revenue	11,758	13,937	(2,179)	(15.63%)
Profit before tax/ (Loss before tax)	178	431	(253)	(58.70%)

The Group recorded a 15.63% decrease in revenue to RM11.7 million in 3Q FY2025 compared to RM13.9 million in 2Q FY2025. The lower revenue recorded is the effect from lower sales to private purchasing segment.

Profit before tax declined by 58.70% to RM178,000 from RM431,000 in the preceding quarter. The lower revenue drags down operating profitability.

UNAUDITED NOTES TO FINANCIAL STATEMENTS

17. COMMENTARY ON CURRENT YEAR PROSPECTS

The Group continues to focus on its core healthcare business, to expand its customer base and margin. External factors such as global economic conditions, currency fluctuations, and evolving customer needs may influence demand patterns in the coming quarters.

The manufacturing facility in Indonesia remains a strategic asset, providing opportunities to broaden the Group's product offerings and expand presence in domestic and regional markets. Operational capacities at the plant continues to improve, expecting to reach commercialisation scale by first quarter next year.

The Group remains focused on executing its growth strategies, maintaining operational discipline, and improve product diversity portfolio to navigate market uncertainties and deliver sustainable performance for the current financial year.

18. PROFIT FORECAST

No profit forecast was announced hence there was no comparison between actual results and forecast.

19. TAXATION

The effective tax rate is lower than the statutory rate due to availability of tax losses brought forward to set off with the taxable income.

	Individual Quarter Ended		**Cumulative Quarter Ended**	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
	RM ('000)	**RM ('000)**	**RM ('000)**	**RM ('000)**
Income tax (expense)/credit	(1)	(4)	(4)	(10)
Deferred tax (liabilities)/assets	-	-	-	-
Total	**(1)**	**(4)**	**(4)**	**(10)**

20. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES

There was no sale of unquoted investments and properties during the current quarter under review.

21. MARKETABLE SECURITIES

There was no purchase or disposal of marketable securities during the current quarter under review.

UNAUDITED NOTES TO FINANCIAL STATEMENTS

22. CORPORATE PROPOSALS

There was no corporate proposal announced which remains uncompleted at the financial period ended 30 September 2025.

23. BANK BORROWINGS AND DEBT SECURITIES

The total bank borrowings of the Group as of the financial period ended 30 September 2025 are as below:

	As at 30-Sep-25 RM ('000)	As at 31-Dec-24 RM ('000)
Non-Current (Secured):		
Term loan	5,471	-
Current (Secured):		
Trade loan	3,315	7,589
Term loan	650	-
	3,965	7,589
Total Bank Borrowings	9,436	7,589

24. CHANGES IN MATERIAL LITIGATION

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

25. EARNINGS PER SHARE

The basic and diluted earnings per share or the reporting period are computed as follows:

a. Basic

	Individual Quarter Ended		Cumulative Quarter Ended	
	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24
Profit attributable to ordinary equity holders of the parent (RM ‘000)	172	663	923	1,309
Weighted average number of ordinary shares in issue (Unit ‘000)	305,572	305,572	305,572	305,572
Basic earnings per share (sen)	0.06	0.22	0.30	0.43

UNAUDITED NOTES TO FINANCIAL STATEMENTS

b. Diluted

There were no diluted earnings per share.

26. PROFIT / (LOSS) BEFORE TAX

Profit / (Loss) before tax is stated after charging/(crediting):

	Individual Quarter Ended		**Cumulative Quarter Ended**	
	30-Sep-25	**30-Sep-24**	**30-Sep-25**	**30-Sep-24**
	RM'000	**RM'000**	**RM'000**	**RM'000**
Other income:-				
Other income	(234)	(230)	(694)	(690)
Interest income	-	(14)	(13)	(225)
Loss on disposal of investment	-	-	-	6
Total	**(234)**	**(244)**	**(707)**	**(909)**
Net foreign exchange loss/(gain)	**(170)**	**(105)**	**(456)**	**(174)**
Interest expenses	**134**	**83**	**385**	**326**

27. REALISED AND UNREALISED PROFITS/LOSSES

The breakdown of the retained profits/losses of the Group as at reporting date into realised and unrealised profits is as follows:

	As at 30-Sep-2025	**As at 30-Sep-2024**
Group's total Retained profits:	**RM'000**	**RM'000**
Realised	304	757
Unrealised	(81)	(2,068)
Total Realised and unrealised	**223**	**(1,311)**
Less: Consol adjustments	(975)	(998)
Accumulated losses	**(752)**	**(2,309)**

UNAUDITED NOTES TO FINANCIAL STATEMENTS

28. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 25th November 2025.

By Order of the Board
Adventa Berhad
CHUA SIEW CHUAN
Company Secretary MAICSA 0777689